AI assistant
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2021
Nov 17, 2021
31868_dirs_2021-11-17_d030f9aa-442d-4f36-a388-7c8b21687cb8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2021-11-15
Reporting Person: ABERCROMBIE GEORGE B (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-11-15 | Common Stock | M | 5000 | $3.32 | Acquired | 5000 | Direct |
| 2021-11-15 | Common Stock | S | 5000 | $12.27 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-11-15 | Automatic Stock Option Grant | $3.32 | M | 5000 | Disposed | 2022-05-23 | Common Stock (5000) | Direct |
Footnotes
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.
F2: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.22 to $12.29. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F3: The option vested 1/12 per month for a period of 12 months, beginning on June 23, 2012.